【Abstract】 Objective To observe the correlation between HFS and therapeutic effect that CAP plus BEV in treatment of HER2negative LR/mBC. Methods 100 HER2negative LR/mBC patients from The Affiliated Hospital of Shanxi University of Traditional Chinese Medicine receiving firstline CAP plus BEV were divided into HFS group and non HFS group according to whether patients with HFS. The survival curves of PFS and OS were plotted by MeierKaplan method. Results Median PFS of HFS group and non HFS group were 10.7 months and 5.8 months, which was statistically significantly different (χ2=23.63, P=0.000). The HFS group did not reach a specific value because the OS minimum survival rate more than 0.50, and median OS from non HFS group was 14.90 months, which was statistically significantly different （χ2=34.04,P=0.000）. The different degree of HFS, PFS and OS survival curves were the highest in patients with grade Ⅱ HFS. Conclusion If the patient appears HFS, especially when the grade II HFS, the prognosis of CAPBEV treatment of patients with Her2negative LR/mBC,will be significantly better than that of the patients without HFS.